Introduction
============

The blood supply to peripheral nerves is delivered by two integrated, but functionally independent, vascular systems.[@b1-jpr-11-227],[@b2-jpr-11-227] Extrinsic and intrinsic vessels form anastomoses at the level of the epineurium. Alterations in blood flow are important for peripheral nerve pathology in acute and chronic disease.[@b3-jpr-11-227]--[@b6-jpr-11-227] Local anesthetics and epinephrine, used as an adjunct, are known to have a negative impact on nerve blood flow.[@b4-jpr-11-227],[@b7-jpr-11-227],[@b8-jpr-11-227] The underlying molecular mechanisms of local anesthetic-induced reductions of nerve blood flow are still uncertain and speculative.[@b9-jpr-11-227] Additionally, it is unclear whether these blood flow reductions, caused by local anesthetics, result in local hypoxic tissue conditions and act as a key factor for peripheral nerve injury.[@b5-jpr-11-227],[@b6-jpr-11-227] The goal of this study is to determine the effect of bupivacaine alone and in combination with the adjuncts epinephrine or clonidine on nerve blood flow and tissue oximetry in a large animal model, simulating human conditions. Thus, data for epinephrine and clonidine, with regard to neural ischemia as a potential risk factor for nerve damage, could be investigated in our study.

Methods
=======

General anesthesia and nerve preparation
----------------------------------------

Experiments were approved by the local authorities (Study No. 93/11; Regional Board of Animal Welfare, Giessen, Germany); study results are presented according to ARRIVE guidelines.[@b10-jpr-11-227] Experiments were performed in accordance with the current German laws of animal protection. Standardized general anesthesia and euthanasia, following the experiments, were conducted as described previously.[@b11-jpr-11-227],[@b12-jpr-11-227] In brief, following a premedication using diazepam and ketamine, general anesthesia was induced using propofol (2--3 mg·kg^−1^ and sufentanil). After endotracheal intubation, general anesthesia was commenced using propofol (0.2 mg·kg^−1^·min^−1^) and sufentanil (0.5 µg kg^−1^ h^−1^). Mechanical ventilation settings were modified to obtain an end tidal CO~2~ of 35--45 mmHg. Inspiratory oxygen fraction was set to 30% (to simulate clinical conditions, using low-flow oxygen supplementation in spontaneously breathing subjects). Ultrasound-guided invasive blood pressure measurement was conducted via catheter to the left femoral artery. To achieve standardized conditions and minimize motion artifacts for the measurements, pancuronium bromide (0.1 mg·kg^−1^) was given repeatedly during the study period. Pharyngeal temperature was recorded and kept constant using warm blankets.

The anesthetized animals were placed supine, and axillary regions were dissected surgically as previously described;[@b11-jpr-11-227],[@b13-jpr-11-227] median nerves were exposed with preservation of the extrinsic epineural blood vessel supply.

Euthanasia was performed at the end of the experiments under general anesthesia using potassium chloride (4 mmol·kg^−1^).

Combined tissue spectrophotometry and laser-Doppler flowmetry
-------------------------------------------------------------

Measurements of nerve blood flow (flow in arbitrary units \[AU\]), tissue oxygen saturation (SO~2~ in %), and tissue hemoglobin level (rHb, in AU) were obtained using laser-Doppler flowmetry and tissue spectrophotometry (O2C; Lea Medizintechnik, Giessen, Germany). The system and probe (LF-1; Lea, Medizintechnik) were calibrated according to the manufacturer's recommendation. The O2C probe was applied to the exposed nerve with a custom-made application device ([Figure 1](#f1-jpr-11-227){ref-type="fig"}), and fixed with sutures in the surrounding tissue for constant application pressure, to acquire a test volume of \~1--2 mm deep inside the nerve, according to the manufacturer's advice. Measurements were started 10 min before each intervention to achieve optimal measurement stability of the system. One milliliter of the randomly assigned test solution was applied directly to the median nerve next to the probe (resulting in spread under the probe due to capillary effects) immediately after acquiring data at T0.

The O2C machine consists of two different units ([Figure 2](#f2-jpr-11-227){ref-type="fig"}). First, blood flow (flow) is measured by using the technique of laser-Doppler flowmetry, which has been described previously.[@b14-jpr-11-227]--[@b16-jpr-11-227] Second, the tissue spectrophotometry unit calculates tissue hemoglobin content and tissue oximetry. In brief, underlying tissue is illuminated with coherent laser light of 500--630 nm wavelength and 30 mW power through a fiber-optic cable. Probe geometry allows for the detection of blood flow at \~1--2 mm depth by analyzing backscattered light. By fitting measured spectra with spectra of known tissue saturation values (SO~2~), the SO~2~ of the capillary and post-capillary microvasculature is calculated by the O2C device. The tissue hemoglobin value (rHb) represents the hemoglobin concentration per tissue volume (displayed as arbitrary unit). It is dependent on microvessel density, venous filling and microvessel shunting. This parameter is helpful to rule out venous congestion (raising rHb value).

Reductions of nerve blood flow are categorized as minimal (\<20% reduction of nerve blood flow \[NBF\] baseline), mild (20%--50% reduction of NBF), moderate (50%--80% reduction of NBF) or severe (\> 80% reduction of NBF) according to structural or electrophysiological signs of tissue damage or electrophysiological conduction impairment as previously described.[@b17-jpr-11-227]--[@b19-jpr-11-227]

Study groups
------------

Randomly, 1 mL of the following test solutions was applied topically to the nerve: bupivacaine 0.5% isobaric (Bupi) (Carbostesin, B. Braun, Melsungen, Germany); bupivacaine 0.5% with epinephrine 1:100.000 (BupiEpi) (Suprarenin, Sanofi-Aventis, Frankfurt, Germany); bupivacaine 0.5% (see previous section) with 3.75 µg/mL clonidine (BupiCloni) (Clonidin-ratiopharm, Ratiopharm, Ulm, Germany). In addition, saline was used as a negative control: saline 0.9% isotonic (NaCl, B. Braun).

Test solutions were prepared freshly before use for the experiments in a standardized fashion using single-dose vials avoiding preparations containing preservatives like sodium metabisulfite. The concentrations of epinephrine and clonidine resemble the highest concentration of epinephrine used in clinical studies.[@b20-jpr-11-227] Only one nerve per exposed brachial plexus was exposed to only one test solution to avoid potential residual drug effects on the sample.

Outcome parameters
------------------

At the time points T0, T5, T10, T15, T20, T25, T30, T40, T50, and T60, the O2C data of blood flow (flow, in AU), tissue oximetry (SO~2~, in percent), and hemoglobin (rHb, in AU) were recorded using Excel (Excel for Mac; Microsoft Corporation, Redmond, WA, USA). Parameters of systemic hemodynamics (heart rate, mean arterial pressure), as well as oxygen saturation were recorded at T0, T30, and T60.

Sample size calculation
-----------------------

Based on published data for nerve blood flow alterations after the application of local anesthetic, we assumed a relative change of nerve blood flow of 1.0 (no change) for saline (negative control group), and compared with T0 and T60 values. Based on published data of nerve blood flow measurements, we assumed a reduction to 0.6 for bupivacaine (standard group), 0.8 for BupiCloni (intervention group), and 0.4 for BupiEpi (intervention group) at T60, compared with baseline flow at T0.[@b9-jpr-11-227] With an assumed standard deviation of 10%, a power of 80%, and a two-sided testing, a minimum number of seven to eight nerves per group were calculated for semi-parametric testing. Due to multiple testing (two comparisons between bupivacaine and each intervention group), the sample size calculation increased to n = 9 per group. Considering a dropout rate due to accidental bleeding or technical problems of data acquisition, we planned to perform measurements in 10 nerves per group.

Exclusion criteria
------------------

Exposed nerves were not used for the experiments when epineural blood vessels were damaged during surgical dissection. Obtained measurements for each given nerve were investigated (blinded to the respective group) for signs of technical problems during the test period, or the baseline period, before starting the test period, and were excluded if: Continuous data acquisition was not correctly performed over the test period for a respective nerve (mostly due to inadvertent probe dislocation).Spectra analysis of the raw data showed incorrect values for hemoglobin extinction (tissue compression due to probe placement).

Statistical analysis
--------------------

Data were analyzed using SPSS (SPSS for Windows, release 18.0). Values for SO~2~ are given as percentage (%) and values for rHb are presented in arbitrary units (AU) according to the manufacturer,[@b21-jpr-11-227] and are presented as absolute values at the given time points. Values for blood flow are presented as relative flow compared to baseline flow measurement, according to previous studies.[@b4-jpr-11-227],[@b9-jpr-11-227]

Values of relative flow (AU), SO~2~ (%), and rHb (AU) at T0, T30, and T60 of bupivacaine (standard group) was compared with either BupiEpi or BupiCloni (experimental groups) using Mann-Whitney *U*-test. The saline group served only as a negative control group in comparison with the bupivacaine group. Statistical tests for differences (two-sided) were deemed significant at a level of 0.05. A closed testing approach was used to compensate for multiple testing: Bonferroni adjustment corrected the level of significance for the two primary comparisons of groups, and the hierarchy of testing according to the primary end points and the time points was relative flow at T60, SO~2~ at T60, rHb at T60, relative flow at T30, SO~2~ at T30, and rHb at T30. Hodges-Lehmann (HL) estimators, with 95% confidence intervals (CI), were calculated for the interpretation of differences between microcirculation parameters (SO~2~ and nerve blood flow) between bupivacaine and each respective group.

Additionally, descriptive post hoc testing was performed comparing SO~2~ and nerve blood flow parameters at T0, T30, and T60 between all groups using the Kruskal--Wallis testing (two-sided testing, level of significance 0.05). In case of significance, pairwise comparisons of the saline group versus bupivacaine, BupiEpi, or BupiCloni groups were performed.

Furthermore, to exclude the potential bias of varying vital parameters between groups, vital parameters at T0, T30, and T60 were compared. In this analysis, HL estimators (95% CI) for heart rate (bpm), mean blood pressure (MAP, mmHg), and SpO~2~ (SpO~2~%) were calculated between the bupivacaine group and one of the respective groups. Differences of less than 10 bpm, 5 mmHg in MAP, or 3% in SpO~2~ among the compared groups were assumed to be clinically irrelevant.

Results
=======

Number of animals and obtained measurements
-------------------------------------------

Fifty-six peripheral nerves (one nerve per brachial plexus) were exposed in 28 pigs. Six nerves were excluded before randomization due to difficulties in probe mounting, or were used for surgical preparation training. According to the predefined criteria for study termination, three peripheral nerves were excluded from the study due to insufficient surgical preparation of the nerve, with suspected injury to the extrinsic nerve vasculature. Furthermore, seven nerves were excluded before data analysis, due to supposed probe dislocation and non-continuous data acquisition. Thus, 40 nerves were randomly assigned to one of the four experimental groups, and included in the final data analysis (n = 10 per group).

Vital parameters
----------------

Vital parameter data are given in [Table 1](#t1-jpr-11-227){ref-type="table"}. Comparison of HL estimators for mean arterial pressure, heart rate, and systemic pulse oximetry revealed no clinically relevant differences between the groups at T0, T30, and T60 min ([Table 1](#t1-jpr-11-227){ref-type="table"}).

Microcirculation (= flow measurements)
--------------------------------------

Analysis of flow parameters is shown in [Table 2](#t2-jpr-11-227){ref-type="table"}. Using the Mann--Whitney test, the bupivacaine group (standard group) showed a significant decrease of flow, compared with the saline group (control group) at T30 and T60 (both *p* \< 0.0001), but was not significantly different from bupivacaine with added clonidine (T30, *p* = 1.0; T60, *p* = 0.19), or with added epinephrine (T30, *p* = 0.48; T60, *p* = 0.39). HL estimators with 95% CI are shown in [Table 2](#t2-jpr-11-227){ref-type="table"}.

Tissue oximetry
---------------

Descriptive data for SO~2~ measurements at time points T0--T60 are presented in [Table 3](#t3-jpr-11-227){ref-type="table"}. Mann--Whitney tests were performed for T0, T30, and T60. No significant differences between the groups were found when comparing bupivacaine with saline at T0 (*p* = 0.472) and T30 (*p* = 0.623), whereas differences between both groups at T60 showed a significant difference (*p* = 0.0005). Comparison of the SO~2~ values of the bupivacaine group with those of the BupiEpi group showed no significant differences at T0 (*p* = 0.382), T30 (*p* = 0.544), or T60 (*p* = 0.130). Moreover, comparison of the SO~2~ results of the bupivacaine group with those of the BupiCloni group revealed no significant differences at T0, T30, or T60 (*p* = 0.519, *p* = 0.520, *p* = 0.211, respectively). The results for comparisons using HL estimators and lower and upper 95% CIs are presented in [Table 3](#t3-jpr-11-227){ref-type="table"}.

Hemoglobin content
------------------

Measurements of rHb as a parameter of venous congestion are shown in [Table 4](#t4-jpr-11-227){ref-type="table"}. No significant differences of rHb were found when comparing bupivacaine with the saline control at the time points T0 (*p* = 0.212), T30 (*p* = 0.226), or T60 (*p* = 0.104). No significant differences were found when comparing the bupivacaine (standard group) with the BupiCloni group (T0, *p* = 0.472; T30, *p* = 0.241; T60, *p* = 0.173) or BupiEpi group (T0, *p* = 0.596; T30, *p* = 0.762; T60, *p* = 0.130).

Post hoc analysis (saline versus active comparator)
---------------------------------------------------

Descriptive post hoc testing was performed comparing SO~2~ as well as nerve blood flow at the given time points between groups. Kruskal--Wallis testing revealed significant differences for nerve blood flow only for T30 (*p* \< 0.0001) and T60 (*p* \< 0.001) but not for T0 (*p* = 1.00). Regarding SO~2~ data, post hoc Kruskal--Wallis testing showed no significant differences between groups for T0 and T30 but a significant difference for T60 (*p* = 0.047).

Thus, pairwise comparisons of saline versus each group (bupivacaine, BupiEpi, or BupiCloni) were performed when applicable. Statistical test results are shown in [Table 5](#t5-jpr-11-227){ref-type="table"}.

Discussion
==========

Our results showed that the application of local anesthetics alone, such as bupivacaine, resulted in relevant nerve blood flow reductions at T30 and T60, as shown in previous studies.[@b4-jpr-11-227],[@b5-jpr-11-227],[@b8-jpr-11-227],[@b9-jpr-11-227],[@b22-jpr-11-227] However, no significant difference for tissue oximetry between bupivacaine versus saline or versus bupivacaine in combination with clonidine or epinephrine was observed. Moreover, the addition of epinephrine or clonidine did not result in any significant alterations of nerve blood flow or tissue oximetry (SO~2~), compared with the bupivacaine standard group.

Epinephrine enhances nerve block duration, mostly due to reduction of local tissue clearance and prolonged concentration of the local anesthetic in the nerve and perineural tissue.[@b7-jpr-11-227] It is regularly used as an adjunct for local anesthetics to reduce systemic absorption and consecutive toxic phenomena of the injected local anesthetic. Furthermore, many clinicians assume a shortened nerve block onset time and prolonged anesthetic nerve blockade when epinephrine is used.[@b20-jpr-11-227]

However, some authors believe that when used as an adjunct, epinephrine might be an independent risk factor for nerve damage due to relevant ischemia.[@b5-jpr-11-227],[@b8-jpr-11-227],[@b23-jpr-11-227] Our study showed no further statistically significant impairment of nerve blood flow (when compared with bupivacaine alone). However, two nerves of the BupiEpi group did have relevant desaturations during measurements (SO~2~ nadir values of 3% at T20 and 10% at T10 in another nerve). Thus, despite no significant difference between both groups of bupivacaine, with and without epinephrine, we would recommend not to use epinephrine in a patient population with preexisting peripheral nerve damage (i.e., diabetic polyneuropathy).

Clonidine is widely used as an adjunct to local anesthetic in different peripheral nerve blockades.[@b20-jpr-11-227],[@b24-jpr-11-227] It prolongs the duration of the blockade due to unknown mechanisms. Due to its alpha-2-adrenergic effects, vasodilatation might be assumed in peripheral tissues, without risk of nerve ischemia. However, clinical side effects, such as sedation or bradycardia, are regularly observed.[@b20-jpr-11-227],[@b25-jpr-11-227] In experimental models of peripheral neuropathy, clonidine acts as an anti-inflammatory drug.[@b26-jpr-11-227]--[@b28-jpr-11-227] Thus, its clinical effects and anti-inflammatory potential are interesting factors for the regional anesthetist. Our experimental data give further evidence of safety when perineural clonidine is used in combination with local anesthetics. No further alterations of nerve microcirculation or tissue oximetry were observed, compared with bupivacaine alone.

Systemic data did not differ, in any way that was clinically relevant, between the time points T0, T30, and T60 when compared between each group. This is important due to the response of nerve SO~2~ to central hypoxia and cardiovascular changes as described by Ibrahim et al.[@b29-jpr-11-227] Moreover, this aspect is a potential bias within previous published studies of nerve blood flow measurements in animals where changes in oxygen saturation and circulation were not, or were inadequately, controlled.

Laser-Doppler flowmetry is an established method for investigating nerve blood flow alterations.[@b4-jpr-11-227],[@b9-jpr-11-227],[@b30-jpr-11-227] Nevertheless, responses of the underlying tissues to blood flow reductions have been poorly investigated for local anesthetic applications. The use of the O2C device enabled us to investigate the consequences of (microvascular) nerve blood flow alterations with regard to local post-capillary oximetry and hemoglobin content as critical parameters for tissue hypoxia and potential tissue damage.

Limitations
-----------

Our experimental study has several limitations, which should be kept in mind before transferring to clinical practice. First, the differences between the results in this animal study might not be easily extrapolated to humans, due to possible differences in nerve blood flow and underlying regulative mechanisms between pigs and humans. Changes in vascular tone might be influenced by general anesthesia, the surgical preparation,[@b31-jpr-11-227] and the mounted probe resting on the nerves. Changes in blood pressure, systemic oxygen saturation, and end tidal carbon dioxide might have an impact on nerve blood flow due to limited autoregulation of nerve blood flow.[@b30-jpr-11-227],[@b32-jpr-11-227] These important bias factors are controlled for in our study by invasive blood pressure monitoring, as well as the use of controlled mechanical ventilation with fixed inspired oxygen fraction, and the use of capnometry for establishing normocapnia. Furthermore, our investigation focused only on median nerves, but potential differences between nerve vasculature must be regarded. However, Kihara et al showed no significant differences between different nerve types or fascicle size.[@b32-jpr-11-227] Our measurements were performed for 60 min, which is higher than in previous studies. Nevertheless, the vasoconstrictive effects of the test solutions persisted for longer time periods. Further studies should evaluate this aspect using long-term measurements and include histological or electrophysiological evaluation. Measurement of compound muscle action potential might be a helpful approach in further studies for assessing the acute and long-term effects of the investigated interventions as shown in previous studies.[@b33-jpr-11-227],[@b34-jpr-11-227] "Downstream" (distal) measurements of overall tissue or nerve tissue perfusion and oxygenation by using near-infrared spectroscopy or other methods as a result of block-related vasodilation might be another interesting topic.[@b35-jpr-11-227]

Neurotoxicity of local anesthetics is not caused solely by ischemia as a result of reduced tissue perfusion. Bupivacaine was shown to be a weak uncoupler of mitochondrial oxidative phosphorylation resulting in apoptosis in neural cells.[@b36-jpr-11-227],[@b37-jpr-11-227]

Conclusion
==========

Based on our experimental study results, the addition of epinephrine or clonidine to bupivacaine does not result in any relevant changes of nerve blood flow, or tissue oximetry, compared with bupivacaine alone. However, bupivacaine does show a relevant depression of nerve blood flow without resulting in severe nerve tissue ischemia. Thus, impairment of nerve blood flow by bupivacaine alone is not modified in a relevant way by the combination of bupivacaine with clonidine. The combination of bupivacaine with epinephrine shows no statistically significant differences in nerve tissue perfusion or tissue oxygen saturation. Ischemia as a consequence of the use of bupivacaine alone or in combination with epinephrine or clonidine was a rare event in our experimental study. Thus, ischemia is not a potential clinical relevant risk factor of peripheral nerve damage resulting from the administration of the aforementioned drugs.

This study was performed by using departmental funding.
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**Abbreviations:** SO~2~, tissue oxygen saturation; rHb, tissue hemoglobin.](jpr-11-227Fig2){#f2-jpr-11-227}

###### 

Vital parameters

  Group                Parameter       T0              HL (95% CI)     T30             HL (95% CI)     T60             HL (95% CI)
  -------------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------
  Bupi (n = 10)        Heart rate      97 (81--108)    n/a             97 (83--99)     n/a             92 (84--102)    n/a
  MAP                  74 (65--79)     n/a             76 (68--86)     n/a             73 (69--83)     n/a             
  SpO~2~               97 (97--99)     n/a             99 (94--100)    n/a             98 (96--100)    n/a             
  Saline (n = 10)      Heart rate      96 (80--103)    −0.5 (−16;22)   89 (77--103)    −4.5 (−19;19)   101 (74--110)   7.5 (−10;25)
  MAP                  71 (59--81)     −2.0 (−14;12)   75 (68--82)     −2 (−12;7)      75 (67--86)     0.5 (−16;22)    
  SpO~2~               100 (96--100)   1.0 (−1;3)      100 (98--100)   0 (0;3)         99 (97--100)    0 (−2;2)        
  BupiCloni (n = 10)   Heart rate      100 (74--105)   −1.5 (−14;12)   97 (76--102)    −0.5 (−15;12)   94 (73--103)    0 (−15;12)
  MAP                  79 (71--86)     3.5 (−8;16)     80 (70--81)     0 (−13;9)       76 (63--89)     1.5 (−11;12)    
  SpO~2~               100 (98--100)   2 (0;3)         100 (98--100)   1 (0;4)         100 (98--100)   0 (−3;0)        
  BupiEpi (n = 10)     Heart rate      95 (84--123)    4.5 (−14;25)    100 (85--114)   5 (−11;23)      101 (88--112)   8 (−6;22)
  MAP                  73 (67--85)     0 (−12;14)      74 (67--80)     −3 (−14;6)      71 (65--78)     −2 (−14;9)      
  SpO~2~               100 (98--100)   2 (0;3)         100 (99--100)   1 (0;3)         100 (99--100)   0 (0;3)         

**Notes:** Heart rate is expressed in bpm; MAP in mmHg; and SpO~2~ in %. All data are given as median (25th--75th percentile), and compares each group with bupivacaine at the same time point, with differences shown as HL estimator, with 95% CI.

**Abbreviations:** Bupi, bupivacaine; BupiCloni, bupivacaine with clonidine; BupiEpi, bupivacaine with epinephrine; CI, confidence interval; HL, Hodges-Lehmann; MAP, mean arterial pressure; n/a, not applicable; Saline, saline control group; SpO~2~, pulse oximetry; T0, time point 0 min; T30, time point 30 min; T60, time point 60 min.

###### 

Relative nerve blood flow

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group         T5                 T10            T15            T20            T25            T30                                                       HL (95% CI)       T40            T50            T60                                                       HL (95% CI)
  ------------- ------------------ -------------- -------------- -------------- -------------- --------------------------------------------------------- ----------------- -------------- -------------- --------------------------------------------------------- -----------------
  Bupivacaine   0.70\              0.61\          0.63\          0.57\          0.55\          0.50\                                                     n/a               0.36\          0.35\          0.33\                                                     n/a
                (0.62--0.97)       (0.50--0.68)   (0.40--0.65)   (0.30--0.63)   (0.27--0.58)   (0.28--0.60)                                                                (0.26--0.54)   (0.24--0.51)   (0.25--0.60)                                              

  Saline        1.02\              1.04\          1.09\          1.04\          1.20\          1.17\                                                     0.738\            1.07\          1.02\          0.86\                                                     0.527\
                (1.01--1.22)^NS^   (0.94--1.09)   (0.93--1.14)   (0.95--1.19)   (0.94--1.28)   (1.11--1.36)[\*](#tfn4-jpr-11-227){ref-type="table-fn"}   (0.541; 0.947)    (0.94--1.30)   (0.79--1.23)   (0.67--1.18)[\*](#tfn4-jpr-11-227){ref-type="table-fn"}   (0.273; 0.857)

  BupiCloni     0.79\              0.71\          0.58\          0.47\          0.44\          0.45\                                                     0.002\            0.38\          0.58\          0.43\                                                     0.117\
                (0.68--0.97)^NS^   (0.59--0.81)   (0.50--0.67)   (0.40--0.63)   (0.32--0.73)   (0.35--0.57)^NS^                                          (−0.185; 0.206)   (0.32--61)     (0.42--0.71)   (0.38--0.63)^NS^                                          (−0.069; 0.312)

  BupiEpi       0.59\              0.45\          0.39\          0.41\          0.41\          0.38\                                                     −0.049\           0.38\          0.39\          0.41\                                                     0.0897\
                (0.27--0.71)^NS^   (0.31--0.61)   (0.34--0.60)   (0.28--0.60)   (0.30--0.56)   (0.27--0.54)^NS^                                          (−0.274; 0.178)   (0.26--0.62)   (0.23--0.62)   (0.30--0.54)^NS^                                          (−0.127; 0.24)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** All data are given as median (25th--75th percentile), and compares each group with bupivacaine at the same time point, with differences shown as HL estimator, with 95% CI. Flow, relative values of flow to baseline flow at T0.

Significant, ^NS^not significant. Level of significance *p* \< 0.05. For details see text.

**Abbreviations:** BupiCloni, bupivacaine with clonidine; BupiEpi, bupivacaine with epinephrine; CI, confidence interval; HL, Hodges-Lehmann Group; n/a, not applicable; Saline, saline control group; T5--T60, time points 5 min to 60 min.

###### 

Tissue oximetry

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group         T0             T5         T10        T15        T20        T25        T30            HL (95% CI)   T40        T50        T60                                                   HL (95% CI)
  ------------- -------------- ---------- ---------- ---------- ---------- ---------- -------------- ------------- ---------- ---------- ----------------------------------------------------- -------------
  Bupivacaine   92\            92\        90.5\      91.5\      92\        90.5\      89\            n/a           84.5\      79.5\      76\                                                   n/a
                (90--98)       (86--95)   (86--95)   (78--95)   (72--95)   (70--93)   (70--94)                     (66--91)   (62--85)   (61--86)                                              

  Saline        89.5\          90\        89.5\      88.5\      88.5\      88.5\      88.5\          3\            90.5\      92\        91.5\                                                 13.5\
                (86--97)^NS^   (84--92)   (83--92)   (84--92)   (85--93)   (86--93)   (86--93)^NS^   (−5; 21)      (87--94)   (87--96)   (84--95)[\*](#tfn7-jpr-11-227){ref-type="table-fn"}   (5; 31)

  BupiCloni     89\            88\        89.5\      89.5\      93\        91\        90\            3\            90\        86\        84.5\                                                 7\
                (89--94)^NS^   (86--94)   (86--91)   (85--94)   (86--95)   (82--94)   (78--96)^NS^   (−9; 20)      (81--95)   (79--94)   (76--91)^NS^                                          (−3; 21)

  BupiEpi       92.5\          83.5\      74\        85.5\      83\        83.5\      85\            −2.5\         87\        90\        91\                                                   8.5\
                (88--95)^NS^   (63--93)   (52--94)   (47--94)   (58--90)   (68--92)   (60--93)^NS^   (−28; 11)     (70--93)   (65--93)   (56--92)^NS^                                          (−16; 26)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** All data are given as median (25th--75th percentile), and compares each group with bupivacaine at the same time point, with differences shown as HL estimator, with 95% CI. SO~2~ is measured in %. Statistical testing was performed for T0, T30, and T60 comparing bupivacaine with the respective group.

Significant, ^NS^not significant. Level of significance *p* \< 0.05. For details see text.

**Abbreviations:** BupiCloni, bupivacaine with clonidine; BupiEpi, bupivacaine with epinephrine; CI, confidence interval; HL, Hodges-Lehmann; n/a, not applicable; Saline, saline control group; SO~2~, tissue oximetry; T0--T60, time points 0 min to 60 min.

###### 

Relative hemoglobin content

  Group         T0                  T5            T10             T15             T20             T25             T30                 T40             T50             T60
  ------------- ------------------- ------------- --------------- --------------- --------------- --------------- ------------------- --------------- --------------- -------------------
  Bupivacaine   65 (46--77)         65 (45--78)   64 (43--68)     62.5 (43--69)   63 (42--69)     62 (40--66)     62.5 (40--67)       55.5 (41--61)   54.5 (42--66)   54 (42--63)
  Saline        73 (65--79)^NS^     70 (55--79)   69 (53--78)     69 (55--77)     68.5 (54--76)   68.5 (56--76)   66.5 (60--76)^NS^   67 (59--75)     67.5 (59--76)   67.5 (59--76)^NS^
  BupiCloni     68.5 (66--70)^NS^   65 (50--69)   66 (56--70)     66 (62--73)     66 (61--73)     64.5 (59--72)   66 (57--85)^NS^     65.5 (61--82)   64.5 (55--77)   65 (59--76)^NS^
  BupiEpi       68.5 (61--74)^NS^   61 (52--64)   65.5 (55--68)   62.5 (52--69)   62.5 (48--69)   58.5 (49--69)   59 (50--69)^NS^     65.5 (49--70)   68 (50--69)     66.5 (52--68)^NS^

**Notes:** Data are given as median (25th--75th percentile). rHb is measured in AU. Statistical testing was performed for T0, T30, and T60 comparing bupivacaine with the respective group.

Significant, ^NS^not significant. Level of significance *p* \< 0.05. For details see text.

**Abbreviations:** AU, arbitrary units; BupiCloni, bupivacaine with clonidine; BupiEpi, bupivacaine with epinephrine; rHb, relative tissue hemoglobin; Saline, saline control group; T0--T60, time points 0 min to 60 min.

###### 

Post hoc comparisons

  Group                 Parameter   T0    T30       T60
  --------------------- ----------- ----- --------- ---------
  Saline vs Bupi        Rel. NBF    n/a   \<0.001   \<0.001
  SO~2~                 n/a         n/a   0.003     
  Saline vs BupiCloni   Rel. NBF    n/a   \<0.001   0.004
  SO~2~                 n/a         n/a   0.63      
  Saline vs BupiEpi     Rel. NBF    n/a   \<0.001   0.001
  SO~2~                 n/a         n/a   0.481     

**Notes:** Data are given as uncorrected *p*-value data of pairwise comparisons using Mann--Whitney testing; n/a due to not significant Kruskal--Wallis testing.

**Abbreviations:** Bupi, bupivacaine; BupiCloni, bupivacaine with clonidine; BupiEpi, bupivacaine with epinephrine; n/a, not applicable; Rel. NBF, relative nerve blood flow; Saline, saline control group; SO~2~, tissue oximetry; T0, time point 0 min; T30, time point 30 min; T60, time point 60 min.
